A detailed history of Van Leeuwen & Company, LLC transactions in Vertex Pharmaceuticals Inc stock. As of the latest transaction made, Van Leeuwen & Company, LLC holds 16,020 shares of VRTX stock, worth $8.05 Million. This represents 3.41% of its overall portfolio holdings.

Number of Shares
16,020
Previous 16,337 1.94%
Holding current value
$8.05 Million
Previous $6.65 Million 0.74%
% of portfolio
3.41%
Previous 3.89%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

SELL
$407.69 - $446.08 $129,237 - $141,407
-317 Reduced 1.94%
16,020 $6.7 Million
Q4 2023

Feb 07, 2024

SELL
$343.0 - $410.68 $11,662 - $13,963
-34 Reduced 0.21%
16,337 $6.65 Million
Q3 2023

Nov 09, 2023

BUY
$338.18 - $362.46 $2.19 Million - $2.34 Million
6,464 Added 65.25%
16,371 $5.69 Million
Q2 2023

Feb 06, 2024

SELL
$314.42 - $351.91 $2.03 Million - $2.27 Million
-6,464 Reduced 39.48%
9,907 $3.49 Million
Q2 2023

Aug 07, 2023

BUY
$314.42 - $351.91 $67,914 - $76,012
216 Added 2.23%
9,907 $3.44 Million
Q1 2023

Feb 06, 2024

BUY
$283.23 - $323.1 $1.83 Million - $2.08 Million
6,444 Added 198.46%
9,691 $3.05 Million
Q1 2023

May 08, 2023

BUY
$283.23 - $323.1 $1.83 Million - $2.08 Million
6,444 Added 198.46%
9,691 $3.05 Million
Q4 2022

Feb 06, 2024

SELL
$285.76 - $321.48 $3.75 Million - $4.22 Million
-13,124 Reduced 80.17%
3,247 $937,000
Q4 2022

Feb 14, 2023

BUY
$285.76 - $321.48 $927,862 - $1.04 Million
3,247 New
3,247 $938,000
Q3 2020

Nov 13, 2020

SELL
$255.65 - $303.1 $1.97 Million - $2.34 Million
-7,719 Closed
0 $0
Q2 2020

Aug 03, 2020

BUY
$225.48 - $295.8 $1.74 Million - $2.28 Million
7,719 New
7,719 $2.24 Million

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $129B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track Van Leeuwen & Company, LLC Portfolio

Follow Van Leeuwen & Company, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Van Leeuwen & Company, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Van Leeuwen & Company, LLC with notifications on news.